PRECISE-ECLS观察性研究:延长静脉-动脉体外膜氧合支持患者的结局与死亡预测
PRECISE-ECLS多中心队列研究纳入546例接受V-A ECMO的患者,其中160例(29%)接受了超过7天的延长支持。延长支持组APACHE IV评分更低(均值79 vs 92),ECMO指征不同,但一年死亡率(61% vs 58%)和一年健康相关生活质量(EQ-5D指数中位数均为0.82)与短期支持组相当。作者构建了包含年龄、APACHE IV、ECMO前心脏骤停、第一周急性肾损伤、第7天累积SOFA评分和脉压的多变量logistic回归模型预测一年死亡率,内部验证后AUROC为0.68,Brier评分为0.22,表现中等。作者认为该模型可能有助于多学科决策是否继续ECMO支持,但待外部验证。
要点
- 在546例V-A ECMO患者中,160例(29%)接受了超过7天的延长支持,延长支持组一年死亡率为58%,短期组(1–7天)为61%。
- 延长支持组与短期支持组的一年健康相关生活质量EQ-5D指数中位数均为0.82。
- 延长支持组APACHE IV评分均值79(SD 29),低于短期支持组的92(SD 36),且ECMO指征不同。
- 预测一年死亡率的模型纳入年龄、APACHE IV、ECMO前心脏骤停、第一周急性肾损伤、第7天累积SOFA评分和脉压,内部验证AUROC为0.68,Brier评分为0.22。
- 作者认为该模型可能有助于多学科决策是否继续ECMO支持,但待外部验证。
适用人群与场景
- 接受V-A ECMO支持作为恢复或长期辅助装置桥接的严重心循环衰竭患者,来自多中心队列(PRECISE-ECLS研究)。
- 延长ECMO组定义为第7天时仍在ECMO上的患者(支持超过7天);短期组为支持1–7天。
研究设计与关键结果
- 多中心队列研究纳入546例患者,160例(29%)接受超过7天的延长V-A ECMO支持。
- 延长支持组APACHE IV评分均值79(SD 29) vs 短期支持组92(SD 36),且ECMO指征不同。
- 一年死亡率:短期支持组(1–7天)61% vs 延长支持组(>7天)58%。
- 一年健康相关生活质量EQ-5D指数中位数:短期支持组0.82(IQR 0.71, 0.91) vs 延长支持组0.82(IQR 0.73, 0.91)。
- 预测一年死亡率的多变量logistic回归模型纳入年龄、APACHE IV、ECMO前心脏骤停、第一周急性肾损伤、第7天累积SOFA评分和脉压,内部验证后AUROC为0.68,Brier评分为0.22。
证据类型、等级与局限
- 证据类型:多中心队列研究(观察性研究)。
- 模型性能中等:AUROC 0.68,Brier评分0.22。
- 局限:模型需外部验证(原文指出pending external validation)。
对床旁实践的改变
- 作者认为,对于第7天仍在V-A ECMO上的患者,基于年龄、APACHE IV、ECMO前心脏骤停、第一周急性肾损伤、第7天累积SOFA评分和脉压的多变量模型可能有助于多学科决策是否继续ECMO支持,但待外部验证。
- 原文显示延长V-A ECMO支持超过7天者一年死亡率(58%)与短期支持者(61%)相当,一年生活质量均较好(EQ-5D指数中位数0.82)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Veno-arterial ExtraCorporeal Membrane Oxygenation (V-A ECMO) as a bridge to recovery or long-term assist devices in severe cardiocirculatory failure typically lasts 5–7 days. There is scarce guidance on which patients benefit from prolonged support, as prediction models are based on parameters at the start of ECMO. We aimed to characterize the subgroup of patients still alive and on ECMO at day 7, and to develop a multivariable prediction model predicting one-year mortality in this subgroup. METHODS: This multicenter cohort study examines the characteristics and outcomes, including quality of life (QoL), of patients receiving short (1–7 days) and prolonged (> 7 days) V-A ECMO support. In patients still on ECMO at day 7 (the prolonged ECMO group), a multivariable logistic regression model was developed to predict one-year mortality. Model performance was evaluated using Area Under the Receiver Operating Characteristic curve (AUROC), Brier score and calibration plot, following internal validation performed via bootstrapping. RESULTS: Out of 546 patients, 160 (29%) underwent prolonged V-A ECMO support. These patients had lower Acute Physiology And Chronic Health Evaluation (APACHE) IV scores (mean 79 [SD 29] vs. 92 [SD 36]) and differed regarding ECMO indication. One-year mortality, (1-7days: 61%, >7days: 58%), and health related QoL at one year (1–7 days: Median EQ-5D index score [IQR] 0.82 [0.71, 0.91], > 7 days: 0.82 [0.73, 0.91]) were comparable between both groups. A multivariable logistic regression model predicting one-year mortality was constructed with age, APACHE IV, pre-ECMO cardiac arrest, acute kidney injury during first week; and cumulative Sequential Organ Failure Assessment (SOFA), and pulse pressure at day 7. The internally validated model showed moderate performance, with an AUROC of 0.68 and a Brier score of 0.22. CONCLUSION: Patients with prolonged V-A ECMO differ in terms of indication and baseline risk scores. Mortality was not higher in patients who received ECMO support for longer than 7 days, and QoL at one year was good in both groups. Our developed multivariable prediction model showed moderate performance in predicting one-year mortality for those still on ECMO at day 7, and may help in multidisciplinary decision-making regarding continuation of ECMO support pending external validation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT 05444764; Registration date: June 22nd, 2022.
参考来源
- Bunge JJH, Pladet LCA, Luijken K, et al. Outcomes and prediction of mortality in patients requiring prolonged veno-arterial extracorporeal membrane oxygenation support in the PRECISE-ECLS observational study. Crit Care. 2026. PMID: 41749286. doi:10.1186/s13054-026-05919-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。